Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other financing activities: 2013-2025

Historic Other financing activities for Aytu Biopharma (AYTU) over the last 6 years, with Sep 2025 value amounting to $114,000.

  • Aytu Biopharma's Other financing activities fell 34.10% to $114,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $980,000, marking a year-over-year decrease of 78.49%. This contributed to the annual value of $576,000 for FY2025, which is 80.23% down from last year.
  • Aytu Biopharma's Other financing activities amounted to $114,000 in Q3 2025, which was down 80.21% from $576,000 recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Other financing activities ranged from a high of $5.0 million in Q2 2023 and a low of -$856,000 during Q2 2021.
  • Its 3-year average for Other financing activities is $1.1 million, with a median of $811,000 in 2024.
  • As far as peak fluctuations go, Aytu Biopharma's Other financing activities plummeted by 792.70% in 2021, and later surged by 621.73% in 2022.
  • Over the past 5 years, Aytu Biopharma's Other financing activities (Quarterly) stood at $1.2 million in 2021, then surged by 149.55% to $3.1 million in 2022, then plummeted by 73.26% to $820,000 in 2023, then crashed by 81.59% to $151,000 in 2024, then crashed by 34.10% to $114,000 in 2025.
  • Its Other financing activities stands at $114,000 for Q3 2025, versus $576,000 for Q2 2025 and $139,000 for Q1 2025.